Primary end points at 1, 3 and 5 years
| At 1 year | At 3 years | At 5 years | |||||||
| TAVR N (%) | SAVR N (%) | HR (95% CI) | TAVR N (%) | SAVR N (%) | HR (95% CI) | TAVR N (%) | SAVR N (%) | HR (95% CI) | |
| All-cause mortality | 388 (14.69) | 505 (5.40) | 1.21 (1.02 to 1.43) | 731 (27.68) | 932 (9.96) | 1.45 (1.28 to 1.64) | 905 (34.27) | 1375 (14.70) | 1.48 (1.33 to 1.65) |
| Non-CV mortality | 181 (6.85) | 211 (2.26) | 1.39 (1.09 to 1.79) | 374 (14.16) | 488 (5.22) | 1.48 (1.24 to 1.75) | 487 (18.44) | 778 (8.32) | 1.48 (1.28 to 1.72) |
| CV mortality | 207 (7.84) | 294 (3.14) | 1.07 (0.85 to 1.35) | 357 (13.52) | 444 (4.75) | 1.42 (1.18 to 1.70) | 418 (15.83) | 597 (6.38) | 1.49 (1.26 to 1.75) |
Cox proportional hazards model reporting HRs for all-cause mortality (competing risk model reporting subdistribution HR for CV and non-CV mortality) and 95% CI occurring from procedure date to 1, 3 and 5 years for patients undergoing TAVR versus SAVR.
CV mortality, cardiovascular mortality; N, the number of events; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.